A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.
Welcome to our interactive training module. Please select from below to
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.
Discuss efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML…
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Fox Chase Cancer Center is pleased to announce the hiring of Simon Sung, MD, as an associate professor in the Department of Pathology.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
